Identification of stemness subtypes and features to improve endometrial cancer treatment using machine learning

References

• Bell DW, Ellenson LH. Molecular genetics of endometrial carcinoma. Annu Rev Pathol. 2019;14:339–367.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA A Cancer J Clin. 2020;70(1):7–30.
   PubMed Web of Science ®Google Scholar
• van den Heerik A, Horeweg N, de Boer SM, et al. Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy. Int J Gynecol Cancer. 2021;31(4):594–604.
   PubMed Web of Science ®Google Scholar
• Malta TM, Sokolov A, Gentles AJ, Cancer Genome Atlas Research Network, et al. Machine Learning identifies stemness features associated with oncogenic dedifferentiation. Cell. 2018;173(2):338–354.e315.
   PubMed Web of Science ®Google Scholar
• Bjerkvig R, Tysnes BB, Aboody KS, et al. Opinion: the origin of the cancer stem cell: current controversies and new insights. Nat Rev Cancer. 2005;5(11):899–904.
   PubMed Web of Science ®Google Scholar
• Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105–111.
   PubMed Web of Science ®Google Scholar
• Bapat SA. Evolution of cancer stem cells. Semin Cancer Biol. 2007;17(3):204–213.
   PubMed Web of Science ®Google Scholar
• Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer. 2012;12(5):323–334.
   PubMed Web of Science ®Google Scholar
• Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell. 2014;14(3):275–291.
   PubMed Web of Science ®Google Scholar
• Nangia-Makker P, Hogan V, Raz A. Galectin-3 and cancer stemness. Glycobiology. 2018;28(4):172–181.
   PubMed Web of Science ®Google Scholar
• Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017;14(10):611–629.
   PubMed Web of Science ®Google Scholar
• Ge Y, Gomez NC, Adam RC, et al. Stem Cell lineage infidelity drives wound repair and cancer. Cell. 2017;169(4):636–650.e614.
   PubMed Web of Science ®Google Scholar
• Esparza R, Azad TD, Feroze AH, et al. Glioblastoma stem cells and stem cell-targeting immunotherapies. J Neurooncol. 2015;123(3):449–457.
   PubMed Web of Science ®Google Scholar
• Carvalho MJ, Laranjo M, Abrantes AM, et al. Endometrial cancer spheres show cancer stem cells phenotype and preference for oxidative metabolism. Pathol Oncol Res. 2019;25(3):1163–1174.
   PubMed Web of Science ®Google Scholar
• Giannone G, Attademo L, Scotto G, et al. Endometrial cancer stem cells: role, characterization and therapeutic implications. Cancers (Basel). 2019;11(11):1820.
   PubMed Web of Science ®Google Scholar
• Dawood S, Austin L, Cristofanilli M. Cancer stem cells: implications for cancer therapy. Oncology (Williston Park). 2014;28(12):1101–1107, 1110.
   PubMed Web of Science ®Google Scholar
• Vander Linden C, Corbet C. Therapeutic targeting of cancer stem cells: integrating and exploiting the acidic niche. Front Oncol. 2019;9:159.
   PubMed Web of Science ®Google Scholar
• Hubbard SA, Gargett CE. A cancer stem cell origin for human endometrial carcinoma? Reproduction. 2010;140(1):23–32.
   PubMed Web of Science ®Google Scholar
• Lu H, Ju DD, Yang GD, et al. Targeting cancer stem cell signature gene SMOC-2 overcomes chemoresistance and inhibits cell proliferation of endometrial carcinoma. EBioMedicine. 2019;40:276–289.
   PubMed Web of Science ®Google Scholar
• Kim M, Lee S, Park WH, et al. Silencing Bmi1 expression suppresses cancer stemness and enhances chemosensitivity in endometrial cancer cells. Biomed Pharmacother. 2018;108:584–589.
   PubMed Web of Science ®Google Scholar
• Kato M, Onoyama I, Yoshida S, et al. Dual-specificity phosphatase 6 plays a critical role in the maintenance of a cancer stem-like cell phenotype in human endometrial cancer. Int J Cancer. 2020;147(7):1987–1999.
   PubMed Web of Science ®Google Scholar
• Johdi NA, Sukor NF. Colorectal cancer immunotherapy: options and strategies. Front Immunol. 2020;11:1624.
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14(10):1014–1022.
   PubMed Web of Science ®Google Scholar
• Marcus A, Gowen BG, Thompson TW, et al. Recognition of tumors by the innate immune system and natural killer cells. Adv Immunol. 2014;122:91–128.
   PubMed Web of Science ®Google Scholar
• Vesely MD, Kershaw MH, Schreiber RD, et al. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011;29:235–271.
   PubMed Web of Science ®Google Scholar
• Marinelli O, Annibali D, Aguzzi C, et al. The Controversial role of PD-1 and its ligands in gynecological malignancies. Front Oncol. 2019;9:1073.
   PubMed Web of Science ®Google Scholar
• Brooks RA, Fleming GF, Lastra RR, et al. Current recommendations and recent progress in endometrial cancer. CA Cancer J Clin. 2019;69(4):258–279.
   PubMed Web of Science ®Google Scholar
• Picard E, Verschoor CP, Ma GW, et al. Relationships between immune landscapes, genetic subtypes and responses to immunotherapy in colorectal cancer. Front Immunol. 2020;11:369.
   PubMed Web of Science ®Google Scholar
• Chen P, Yang Y, Zhang Y, et al. Identification of prognostic immune-related genes in the tumor microenvironment of endometrial cancer. Aging (Albany NY). 2020;12(4):3371–3387.
   PubMedGoogle Scholar
• Li BL, Wan XP. Prognostic significance of immune landscape in tumour microenvironment of endometrial cancer. J Cell Mol Med. 2020;24(14):7767–7777.
   PubMed Web of Science ®Google Scholar
• Xu L, Deng C, Pang B, et al. TIP: a web server for resolving tumor immunophenotype profiling. Cancer Res. 2018;78(23):6575–6580.
   PubMed Web of Science ®Google Scholar
• Starzer AM, Preusser M, Berghoff AS. Immune escape mechanisms and therapeutic approaches in cancer: the cancer-immunity cycle. Ther Adv Med Oncol. 2022;14:17588359221096219.
   Web of Science ®Google Scholar
• Tang S, Ning Q, Yang L, et al. Mechanisms of immune escape in the cancer immune cycle. Int Immunopharmacol. 2020;86:106700.
   PubMed Web of Science ®Google Scholar
• Cancer stat facts: Uterine cancer. National Cancer Institute. Available at: https://seer.cancer.gov/statfacts/html/corp.html. (Accessed on September 28, 2019).
   Google Scholar
• Signorelli M, Lissoni AA, Cormio G, et al. Modified radical hysterectomy versus extrafascial hysterectomy in the treatment of stage I endometrial cancer: results from the ILIADE randomized study. Ann Surg Oncol. 2009;16(12):3431–3441.
   PubMed Web of Science ®Google Scholar
• Nout RA, Smit VT, Putter H, PORTEC Study Group, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010;375(9717):816–823.
   PubMed Web of Science ®Google Scholar
• de Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(3):295–309.
   PubMed Web of Science ®Google Scholar
• National Comperhensive Cancer Network. Available online: https://www.nccn.org/professionals/physician_gls/pdf/uterine_blocks.pdf. (Accessed on September 28, 2019).
   Google Scholar
• Fung-Kee-Fung M, Dodge J, Elit L, Cancer Care Ontario Program in Evidence-based Care Gynecology Cancer Disease Site Group, et al. Follow-up after primary therapy for endometrial cancer: a systematic review. Gynecol Oncol. 2006;101(3):520–529.
   PubMed Web of Science ®Google Scholar
• Lajer H, Jensen MB, Kilsmark J, et al. The value of gynecologic cancer follow-up: evidence-based ignorance? Int J Gynecol Cancer. 2010;20(8):1307–1320.
   PubMed Web of Science ®Google Scholar
• Banz-Jansen C, Helweg LP, Kaltschmidt B. Endometrial cancer stem cells: where do We stand and where should We go? Int J Mol Sci. 2022;23(6):3412.
   PubMed Web of Science ®Google Scholar
• Friel AM, Sergent PA, Patnaude C, et al. Functional analyses of the cancer stem cell-like properties of human endometrial tumor initiating cells. Cell Cycle. 2008;7(2):242–249.
   PubMed Web of Science ®Google Scholar
• Witte KE, Hertel O, Windmöller BA, et al. Nanopore Sequencing reveals global transcriptome signatures of mitochondrial and ribosomal gene expressions in various human cancer stem-like cell populations. Cancers (Basel). 2021;13(5):1136.
   PubMed Web of Science ®Google Scholar
• Kusunoki S, Kato K, Tabu K, et al. The inhibitory effect of salinomycin on the proliferation, migration and invasion of human endometrial cancer stem-like cells. Gynecol Oncol. 2013;129(3):598–605.
   PubMed Web of Science ®Google Scholar
• Dong P, Konno Y, Watari H, et al. The impact of microRNA-mediated PI3K/AKT signaling on epithelial-mesenchymal transition and cancer stemness in endometrial cancer. J Transl Med. 2014;12:231.
   PubMed Web of Science ®Google Scholar
• Gao Y, Liu T, Huang Y. MicroRNA-134 suppresses endometrial cancer stem cells by targeting POGLUT1 and notch pathway proteins. FEBS Lett. 2015;589(2):207–214.
   PubMed Web of Science ®Google Scholar
• Howitt BE, Shukla SA, Sholl LM, et al. Association of polymerase e-Mutated and Microsatellite-Instable endometrial cancers with neoantigen load, number of Tumor-Infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol. 2015;1(9):1319–1323.
   PubMed Web of Science ®Google Scholar
• Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–413.
   PubMed Web of Science ®Google Scholar
• Ott PA, Bang YJ, Berton-Rigaud D, et al. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-Positive endometrial cancer: results from the KEYNOTE-028 study. J Clin Oncol. 2017;35(22):2535–2541.
   PubMed Web of Science ®Google Scholar
• Fleming GF, Emens LA, Eder JP, et al. Clinical activity, safety and biomarker results from a phase Ia study of atezolizumab (atezo) in advanced/recurrent endometrial cancer (rEC). J Clin Oncol. 2017;35(15_suppl):5585–5585.
   Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with Mismatch-Repair deficiency. N Engl J Med. 2015;372(26):2509–2520.
   PubMed Web of Science ®Google Scholar